Personalized cancer vaccine for non-small cell lung cancer after surgery
Part of Cancer, Immune system & allergy, Lungs & breathing clinical trials.
This trial tests a personalized cancer vaccine, given alone or with an immunotherapy drug called toripalimab, in people with non-small cell lung cancer (NSCLC) who have had surgery and are getting adjuvant therapy (treatment to prevent the cancer from coming back). The goal is to see if the vaccine is safe and may help the immune system fight any remaining cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with non-small cell lung cancer (NSCLC) and are getting treatment to help prevent it from coming back after surgery (called adjuvant or perioperative therapy).
- You are generally able to take care of yourself (ECOG score 0-1) and are expected to live at least 6 more months.
- You have not had any other cancer treatment (like chemo or immunotherapy) for your lung cancer before your current adjuvant therapy.
- You have not had certain lung conditions like interstitial lung disease, tuberculosis, or any active infections, and you do not have a history of severe heart or blood vessel problems within the past 6 months.
- For women: You are not pregnant, not breastfeeding, and you agree to use effective birth control during the study. For men: You agree to use effective birth control as well.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized vaccine designed to train your immune system to fight any remaining cancer cells after surgery or during standard therapy. It is for people with solid tumors who are stable and have no signs of disease getting worse.
This trial tests a personalized mRNA vaccine (made from your own tumor's genetic fingerprint) combined with an immunotherapy drug called adebrelimab. The goal is to see if this combination can help prevent lung cancer from coming back or slow its growth.
This trial tests a personalized cancer vaccine, made specifically for your tumor, combined with a medicine called toripalimab (which helps your immune system fight cancer). It is designed for people who have had surgery for a solid tumor and are getting additional therapy to try to prevent the cancer from coming back.
This trial tests a combination of medicines given before surgery and immunotherapy after surgery for resectable non-small cell lung cancer (NSCLC). It aims to shrink the tumor before the operation and reduce the risk of cancer coming back after surgery.
This trial compares two different drug combinations given before surgery for stage II-III non-small cell lung cancer (NSCLC). Both combinations include chemotherapy, and one also includes a newer type of immunotherapy. The goal is to see which approach shrinks tumors more effectively before surgery.
This trial tests a new combination of radiation, two immunotherapy drugs, and chemotherapy given before surgery for non-small-cell lung cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients with stage II-III disease that can be removed with surgery.
Hear when a new Non-Small Cell Lung Cancer NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.